Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

atment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and men must use two forms of effective contraception during treatment and during the 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. If pregnancy should occur during treatment or during 6 months post-therapy, the patient must be advised of the significant teratogenic risk of COPEGUS therapy to the fetus. Healthcare providers and patients are strongly encouraged to immediately report any pregnancy in a patient or partner of a patient during treatment or during 6 months after treatment cessation to the Ribavirin Pregnancy Registry at 1-800-593-2214.

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score greater than or equal to 6) is observed.

The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Laboratories, Inc. (Nasdaq: CBRX ) ("Columbia" or ... manufacturing, and advanced analytical and consulting services to the ... the upcoming Rodman & Renshaw 16 th Annual ... New York . The Company will present at ... the New York Palace Hotel. To ...
(Date:8/27/2014)... 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over the ... for the quarter of $240,156 compared to net income of ... For the nine months ended June 30, 2014: ...
(Date:8/27/2014)... PASADENA, Calif. , Aug. 27, 2014  After ... Compensation and Personal Injury billing solution for medical ... extremely positive response toward the new software. ... Development Sandy Thompson . "The sheer number of ... how true the need was for these types of ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3
... Pa., Sept. 18 ,Interleukin Genetics, Inc. (Amex: ... research collaboration to explore the role of genetics ... develop a series of genetic,tests that will help ... loss and, more specifically, gauge a patient,s,likelihood of ...
... Assess Effectiveness of Cladribine Tablets, in Preventing Conversion to Definite Multiple Sclerosis in Addition ... Fully Enrolled Phase III Pivotal Trial - ... - the CLARITY Study - ... GENEVA, Sept. 18 Merck Serono, a division of Merck,KGaA, Darmstadt, Germany, announced today ...
Cached Medicine Technology:Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success 2Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success 3Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis 2Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis 3Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis 4Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis 5
(Date:8/28/2014)... (PRWEB) August 28, 2014 MarijuanaDoctors.com is ... physician, James Patel M.D. of Livermore, California. As always, ... and most qualified physicians, and in accordance with that, ... patients to Dr. Patel’s practice. , Initially finding his ... young age, Dr. Patel was shaped by his mother’s ...
(Date:8/28/2014)... The need for larger space has become more ... The new location - 4700 Bryant Irvin Court, Fort Worth, ... space than TLC had in the past, as well as ... our new location because it represents a good fit for ... in size compared to the current one, the building itself ...
(Date:8/27/2014)... 2014 Author and orthopedic surgeon William ... on the thrilling adventures of sharp and witty ... is gearing up for a new marketing push in ... novellas , “Prescription: Murder” follows the adventures of ... dodging assassination attempts and thwarting criminals. In the first ...
(Date:8/27/2014)... 28, 2014 Recently, BambooIndustry.com, an innovative company ... announced that new bamboo panels are now offered ... deep discounts for clients worldwide. All people that place an ... rate, from 10 to 30 percent off. , The ... panels. “At the moment, all our new and old customers ...
(Date:8/27/2014)... National Resident Matching Program International (NRMPI) ... Education in Europe (AMEE) Conference being held at the ... September 3, 2014. As an exhibitor, NRMPI will ... share the benefits of its matching services, and discuss ... countries throughout the world. , “Exhibiting at ...
Breaking Medicine News(10 mins):Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:William H. Simon Launches New Marketing Campaign for Book 2Health News:BambooIndustry.com: Cheap Bamboo Panels for Clients Worldwide Offered Online 2Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2
... WASHINGTON, Sept. 9 As Obama prepares to address the nation ... nation,s Catholic bishops to be prepared to shut down Catholic health ... compromising with the intrinsic evils currently contained in various Obamacare proposals. ... ) , , "Obama speaks tonight. ...
... , A Public Briefing, Saturday, September 19, 2009 , ... , 529 14th Street, NW , Washington D.C. 20045 ... number of organizations are joining in briefings on health care reform that would ... individual rights and choices of Americans. This will provide a stark contrast ...
... UNION CITY, Calif., Sept. 9 Abaxis, Inc. (Nasdaq: ... systems, announced today that Clint Severson, chairman and chief executive officer, ... 2009 on Thursday, September 17, 2009 at 10:00 a.m. ET. The ... New York City. , , About Abaxis ...
... , , , CHICAGO, ... to the long-term care industry, today announced it was named to ... privately held companies in the United States for the third consecutive year. ... 2005 through 2008 and is the only long-term care pharmacy services provider ...
... , CHAPEL HILL, N.C., Sept. 9 TSI ... healthcare information technology, was recently recognized in Inc. Magazine,s ... nation. Some of the most successful and innovative businesses in America ... SAS, Intuit, and Nike. , , ...
... , , CINCINNATI, Sept. 9 ... know that healthful aging depends on our current habits. "Our ... take precautionary measures to strengthen ourselves," explains the women,s health expert ... are all areas that are often overlooked or taken for granted ...
Cached Medicine News:Health News:A.L.L.: Bishops Must Choose Between Christ-Centered Care and Obamacare 2Health News:Joint Briefing on Proposed Health Care Reform 2Health News:Joint Briefing on Proposed Health Care Reform 3Health News:Millennium Pharmacy Systems Named to Inc. 500 for Third Consecutive Year 2Health News:TSI Healthcare Recognized by Inc. Magazine 2Health News:Leading Women's Health Expert Offers Preventive Tips for Healthful Aging 2Health News:Leading Women's Health Expert Offers Preventive Tips for Healthful Aging 3Health News:Leading Women's Health Expert Offers Preventive Tips for Healthful Aging 4
Black multi-pinhole occluder...
9 inch double ended with one end black and the other end with 49 holes...
Double Ended Occluders...
49 pinholes, black...
Medicine Products: